Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider

Latest news

Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive...
San Diego, October 17th 2017 - Ignyta, Inc. - Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
Read


FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)
San Diego, October 9th 2017 - Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) granted an orphan drug designation to PCM-075 for the treatment of patients with acute myeloid leukemia (AML) on September 28, 2017. PCM-075 is an oral, highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine Polo-like Kinase 1 (PLK1) enzyme, which appears to be over expressed in several different hematologic malignancies and solid tumor cancers."
Read


'Open Day Open Science', nel campus di Nerviano un evento dedicato agli studenti in occasione della Biotech Week

Nerviano, 19 Settembre  Nerviano Medical Sciences parteciperà alla prossima Biotech Week, la settimana di eventi e manifestazioni dedicati al settore delle biotecnologie, con un evento dedicato agli studenti delle scuole superiori. L'iniziativa ha l’obiettivo di celebrare il ruolo chiave di queste tecnologie e i successi della ricerca.

"E' un orgoglio essere parte di questa iniziativa mondiale, - ha commentato il Dr. Agazzi - che nel 2015 ha ottenuto la “Medaglia del Presidente della Repubblica” quale premio di rappresentanza e quest’anno gode del patrocinio del Senato della Repubblica. Per questa edizione abbiamo pensato di aprire le porte del Campus agli studenti per l'importanza che riconosciamo al mondo della Scuola e l'interesse e curiosità che da sempre I ragazzi riservano alla attività del Centro. Inoltre, - conclude Agazzi - siamo lieti e orgogliosi di partecipare a questa inziativa insieme a diversi partner istituzionali quali l'Associazione europea delle imprese biotech che l'ha lanciata una decina di anni fa in Canada, EuropaBio che l'ha importata nella Comunità Europea nel 2013 in occasione del 60° anniversario della scoperta della struttura DNA e Assobiotec che la coordina a livello nazionale."

Di seguito il programma completo della manifestazione.


ebw programma


Trovagene announces Manufacturing Agreement with NerPharMa for Supply of PCM-075 for AML Trial
San Diego, June 29th 2017 - Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced it has executed a supplier agreement with NerPharMa, S.r.l., a pharmaceutical manufacturing company and a subsidiary of Nerviano Medical Sciences S.r.l., in Milan, Italy, to manufacture drug product for PCM-075.
Read
Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
San Diego, May 15th 2017 - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to entrectinib "for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or who have no acceptable standard therapies."
Read


Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer (2)

San Diego, October 17th 2017 - Ignyta, Inc. - Interim Analysis of Ignyta's Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
Read


 
Vinaora Nivo SliderVinaora Nivo Slider

Nerviano Medical Sciences

Nerviano Medical SciencesHeart of the innovative Group focused on the identification of new therapeutic strategies, research and development of new drugs, shapes the future of the oncology.
www.nervianoms.com

Accelera

AcceleraAn Italian preclinical research Company, recognized and certified, all over the world provides high standard integrated services, with reliability and international compliance.
www.accelera.org

Clioss

CliossWith an extensive experience, Clioss partners worldwide Biopharma, Biotech and Research Institutions for full cycle drug development from First-Time-In-Man.

www.clioss.com

NerPharMa

NerpharmaConsolidated know-how, the highest quality standards characterize the offered services: for the formulation, the registration and the production of the active principle.
www.nerpharma.com

To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.